Compare FTEK & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTEK | GRML |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Pollution Control Equipment | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.1M | 51.5M |
| IPO Year | 1997 | 2022 |
| Metric | FTEK | GRML |
|---|---|---|
| Price | $1.37 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 187.9K | ★ 3.6M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,467,000.00 | N/A |
| Revenue This Year | $14.17 | N/A |
| Revenue Next Year | $11.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $0.27 |
| 52 Week High | $3.64 | $0.55 |
| Indicator | FTEK | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 32.07 |
| Support Level | $1.17 | $0.28 |
| Resistance Level | $1.52 | $0.42 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.00 | 4.74 |
Fuel Tech Inc is a technology provider of boiler optimization, efficiency improvement, and air pollution reduction to utility and industrial customers. The company operates in two segments, Air Pollution Control and Fuel Chem. The Air Pollution Control technology segment includes technologies to reduce NOx emissions in flue gas from boilers, incinerators, furnaces, and other stationary combustion sources. The Fuel Chem technology segment uses chemical processes in combination with Computational Fluid Dynamics and Chemical Kinetics Modeling for boiler modeling for the control of slagging, fouling, corrosion, opacity and other sulfur trioxide-related issues in furnaces and boilers through the addition of chemicals into the furnace using TIFI Targeted In-Furnace Injection technology.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.